Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-622-7 | CAS number: 85-68-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Remarks:
- Not sensitising - Migrated information - See Material and Method
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 3 December 1979 to 8 February 1980
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: No guideline is available for the conduct of sensitization testing in humans
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Shelanski HA and Shelanski MD (1953). A new technique of human patch tests. Proceedings of the Scientific Section of the Toilet Goods Association, No. 19, 46-49.
Substance applied to a patch of at least 6.5 square cm for 24 hr on 3 days/week for a total of 5 weeks, allowing the skin to recuperate for 24 hr between exposures. 2-3 weeks after the final induction treatment the test substance is reapplied for usually 48 hr. This method was reported to detect not only primary sensitizers and primary irritants but also cumulative irritants. - GLP compliance:
- not specified
- Type of study:
- patch test
- Justification for non-LLNA method:
- The LLNA method was not available yet by the time the study was conducted
- Species:
- human
- Sex:
- male/female
- Route:
- epicutaneous, occlusive
- Vehicle:
- unchanged (no vehicle)
- Route:
- epicutaneous, occlusive
- Vehicle:
- unchanged (no vehicle)
- No. of animals per dose:
- 200 human subjects completed the single dose study (out of 208 that started it)
- Details on study design:
- MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 15
- Exposure period: 24 hr
- Test groups: Two groups each receiving the same treatment
- Control group: no
- Site: no data
- Frequency of applications: three times weekly on alternate weekdays for 3 weeks, then a 2-week break (during Christmas period) followed by a further 2 weeks of thrice weekly application
- Concentrations: 0.2 ml of undiluted test substance
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 2 weeks after the last induction exposure
- Exposure period: 24 hr
- Test groups: Two groups each receiving the same treatment
- Control group: no
- Site: no data; new site to that used for induction
- Concentrations: 0.2 ml of undiluted test substance
- Evaluation (hr after challenge): 0, 24, 48 and 72 hr by testing laboratory, then self assessment for a further week. - Challenge controls:
- no
- Positive control substance(s):
- no
- Remarks:
- not ethical
- Reading:
- 1st reading
- Hours after challenge:
- 0
- Group:
- negative control
- Dose level:
- 0.2 ml of undiluted test substance
- No. with + reactions:
- 0
- Total no. in group:
- 0
- Clinical observations:
- no effects
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 0.0. Group: test group. Dose level: 0.2 ml of undiluted test substance. No with. + reactions: 0.0. Total no. in groups: 200.0. Clinical observations: no effects.
- Reading:
- 1st reading
- Hours after challenge:
- 0
- Group:
- test chemical
- Dose level:
- 0.2 ml of undiluted test substance
- No. with + reactions:
- 0
- Total no. in group:
- 200
- Clinical observations:
- no effects
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 0.0. Group: test group. Dose level: 0.2 ml of undiluted test substance. No with. + reactions: 0.0. Total no. in groups: 200.0. Clinical observations: no effects.
- Reading:
- 2nd reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 0.2 ml of undiluted test substance
- No. with + reactions:
- 0
- Total no. in group:
- 200
- Clinical observations:
- no effects
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 24.0. Group: test group. Dose level: 0.2 ml of undiluted test substance. No with. + reactions: 0.0. Total no. in groups: 200.0. Clinical observations: no effects.
- Reading:
- other: 3rd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 0.2 ml of undiluted test substance
- No. with + reactions:
- 0
- Total no. in group:
- 200
- Clinical observations:
- no effects
- Remarks on result:
- other: Reading: other: 3rd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0.2 ml of undiluted test substance. No with. + reactions: 0.0. Total no. in groups: 200.0. Clinical observations: no effects.
- Reading:
- other: 4th reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- 0.2 ml of undiluted test substance
- No. with + reactions:
- 0
- Total no. in group:
- 200
- Clinical observations:
- no effects
- Remarks on result:
- other: Reading: other: 4th reading. . Hours after challenge: 72.0. Group: test group. Dose level: 0.2 ml of undiluted test substance. No with. + reactions: 0.0. Total no. in groups: 200.0. Clinical observations: no effects.
- Reading:
- 1st reading
- Hours after challenge:
- 0
- Group:
- positive control
- Dose level:
- 0.2 ml of undiluted test substance
- No. with + reactions:
- 0
- Total no. in group:
- 0
- Clinical observations:
- no effects
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 0.0. Group: test group. Dose level: 0.2 ml of undiluted test substance. No with. + reactions: 0.0. Total no. in groups: 200.0. Clinical observations: no effects.
- Interpretation of results:
- not sensitising
- Remarks:
- Migrated information
- Conclusions:
- Santicizer 160 (butyl benzyl phthalate) showed no sensitizing potential when applied to the skin of 200 human volunteers in a repeated-dose patch test.
- Executive summary:
Santicizer 160 (butyl benzyl phthalate) was assessed for its skin sensitizing potential in humans using a repeated insult patch test method.
During the induction phase 200 healthy volunteers were exposed to 0.2 ml of the undiluted test substance applied to an occusive patch for 24 hours on fifteen separate occasions; after a 2 week period the same dose was applied as a challenge (24 -hour covered) to a new area of the skin. The skin was assessed for irritation after each induction exposure and for sensitization 0, 24, 48 and 72 hours after the challenge.
No evidence of sensitization (or irritation) was reported for any of the volunteers during the study.
Santicizer 160 (butyl benzyl phthalate) showed no skin sensitization (or irritation) potential in healthy human subjects in a repeated insult patch test.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Santicizer 160 (BBP) showed no skin sensitisation potential in a human repeated insult patch test. During the induction phase, 200 healthy volunteers were exposed to 0.2 ml of the undiluted test material applied to an occlusive patch for 24 hours on fifteen separate occasions; after a 2 -week period, the same dose was applied as a challenge (24 -hour covered contact) to a new area of the skin. The skin was assessed for irritation after each induction exposure and for sensitisation 0, 24, 48 and 72 hours after the challenge. No evidence of sensitisation was observed by the investigators or reported by any of the volunteers during the study (Shelanski, 1980).
In a reliable study, no skin sensitisation was seen in guinea pigs after intradermal induction and epicutaneous challenge with BBP.
Induction involved intradermal injection of BBP (1 mM) with Freunds Complete Adjuvant into the four footpads of each of 4 guinea pigs. Epicutaneous challenges were applied, 14 days later, to the shaved abdominal skin of each animal, with three concentrations of BBP (3.6, 36 and 360 mM) and of the vehicle (acetone/corn oil). The skin was washed after 18 hours and skin reactions were read 24 and 48 hours after the start of the challenge exposure. Approximately 5 weeks later, a rechallenge using the highest concentration was made and skin reactions read at 48 hours. Four guinea pigs were treated with a positive control substance, 2,4 -dinitrofluorobenzene, in the same way. BBP did not induce skin reactions at any of the challenge sites, whereas clear positive responses were seen in the positive control animals (Little, 1983a).Two other reliable studies, both ear swelling tests involving epicutaneous administration of BBP to the skin of AKR and BALB/c mice and subsequent challenge application to the ears, showed no evidence of skin sensitisation (Little, 1983b,c).
Migrated from Short description of key information:
Benzyl butyl phthalate (BBP) has shown no evidence of skin sensitisation potential in a human repeated insult patch test or in laboratory animal studies (a guinea-pig footpad test and two mouse ear swelling tests). Although none of these are guideline studies, all appear to be reliable with restrictions (reliability code 2).
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The potential for respiratory tract sensitisation by butyl benzyl phthalate (BBP) and certain other phthalate esters (DEHP, DINP and di-isohexyl phthalate) was investigated in B6C3F1 mice using an experimental procedure developed by Dearman et al., 1992 (J. Appl. Toxicol. 12(5), 317 -323). Repeated dermal applications of these four phthalates did not increase serum levels of IgE or of the interleukins IL-4 or IL-13, in contrast to the effects observed with the known respiratory sensitiser, trimellitic anhydride. Based on these results, it was concluded that these phthalates "have little, if any, potential to produce antibody-mediated respiratory allergy" (Butala et al., 2004).
A more recent study by Dearman et al. (2009) assessed the strength of immune responses induced in BALB/c mice immunised subcutaneously with the reference allergen ovalbumin, when they received a concurrent topical application of BBP. When the BBP was applied either near to or distant from the site of ovalbumin immunisation, it had no impact on anti-ovalbumin IgE antibody responses. However, when applied at the same site as the immunisation, the high dose of BBP (100 mg) did produce a modest increase in anti-ovalbumin IgG1 antibody production, in the absence of any effect on IgE antibody production. The investigators concluded that "the doses of phthalate [BBP] encountered in the home environment are unlikely to be a major factor contributing to the increased incidence of asthma and allergy in the developed world" (J. Appl. Toxicol. 2009, 29(2), 118 -125).Migrated from Short description of key information:
Data on butyl benzyl phthalate and other phthalate esters do not indicate a potential for respiratory tract sensitisation (Butala et al., 2004; Dearman et al. 2009). In addition, as the high-molecular-weight phthalates have provided no indication of skin sensitisation, a respiratory sensitising effect is considered unlikely. The low vapour pressures of these substances provide additional reassurance, as exposure by inhalation is likely to be minimal.
Justification for classification or non-classification
Based on the available data, BBP does not need to be classified as a sensitiser.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.